US Government Signs COVID-19 Vaccine Pact With Novavax, With FDA Decision Still Pending

Novavax Inc  (NASDAQ: NVAX) has announced an agreement with the U.S. Department of Health and Human Services, in collaboration with the Department of Defense, to secure an initial 3.2 million doses  of its COVID-19 vaccine. The agreement is conditional on receiving FDA Emergency Use Authorization (EUA) and a recommendation from the Centers for Disease Control and Prevention.  Novavax's protein-based vaccine will be free to states, jurisdictions, federal pharmacy partners, and federally qualified health centers. Related:   Full story available on Benzinga.com